Effect of drug Rosuvastatin When given in addition to the existing treatment in patients of skin disease (chronic plaque psoriasis)

Efficacy and safety of Rosuvastatin as an add on therapy in patients of chronic plaque psoriasis: a non-randomized, assessor blind, controlled clinical trial - Ros P2 Trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/02/049424

Enrollment

Registered

2023-02-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L408- Other psoriasis

Interventions

Intervention1: Tab Rosuvastatin: Patients of Chronic Plaque Psoriasis will be evaluated for statin eligibility depending on American Heart Association/ American College of Cardiology(AHA/ACC) guidelin

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients having Chronic Plaque Psoriasis with Body surface area involvement of 10 percent or greater 2)Patients who are willing to give written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients with present or past history of clinical atherosclerotic cardiovascular disease 2)Patients having deranged Liver Tunction test(LFT)/ Active liver disease(ALD) 3)Patients having clinical features suggestive of myopathy 4)Patients having known allergy to statins 5)Patients who are already on statins 6)Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Psoriatic Area and Severity Index(PASI) ScoreTimepoint: Baseline, 4 weeks, 8 weeks and 12 weeks	—

Secondary

Measure	Time frame
Dermatology Life and Quality Index (DLQI)Timepoint: Baseline and 12 weeks;High sensitivity- C reactive protein (hs-CRP)Timepoint: Baseline and 12 weeks;Lipid ProfileTimepoint: Baseline and 12 weeks;PASI 50Timepoint: At the end of 12 weeks	—

Countries

India

Contacts

Public ContactDr Shaveta Siwach

Pt BD Sharma, PGIMS Rohtak

drniti.mittal@gmail.com8059840290

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026